• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

作者信息

Attauabi Mohamed, Seidelin Jakob, Burisch Johan

机构信息

Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark

Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Copenhagen, Denmark.

出版信息

Gut. 2021 Oct;70(10):2020-2022. doi: 10.1136/gutjnl-2021-324397. Epub 2021 Mar 3.

DOI:10.1136/gutjnl-2021-324397
PMID:33658323
Abstract
摘要

相似文献

1
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?炎症性肠病患者使用5-氨基水杨酸酯与重症新型冠状病毒肺炎风险之间的关联：研究方法的人为结果？
Gut. 2021 Oct;70(10):2020-2022. doi: 10.1136/gutjnl-2021-324397. Epub 2021 Mar 3.
2
The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.美沙拉嗪与尼古丁在炎症性肠病治疗中的作用
Ann Pharmacother. 1997 Jul-Aug;31(7-8):907-13. doi: 10.1177/106002809703100719.
3
[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].[5-氨基水杨酸在溃疡性结肠炎和克罗恩病治疗中的应用]
Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2565-7.
4
Controversies with aminosalicylates in inflammatory bowel disease.氨基水杨酸类药物在炎症性肠病中的争议
Rev Gastroenterol Disord. 2004 Summer;4(3):104-17.
5
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.儿童炎症性肠病中 SARS-CoV-2 感染的良性演变：来自两个国际数据库的结果。
Clin Gastroenterol Hepatol. 2021 Feb;19(2):394-396.e5. doi: 10.1016/j.cgh.2020.10.010. Epub 2020 Oct 12.
6
[5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].5-氨基水杨酸在溃疡性结肠炎和克罗恩病中的应用（作者译）
Dtsch Med Wochenschr. 1982 Jul 23;107(29-30):1131-4. doi: 10.1055/s-2008-1070088.
7
Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.炎症性肠病患者幽门螺杆菌感染率的评估。
Eur J Gastroenterol Hepatol. 2000 Apr;12(4):439-43. doi: 10.1097/00042737-200012040-00012.
8
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.中国炎症性肠病患者的癌症风险和化学预防：一项基于人群的队列研究。
Scand J Gastroenterol. 2020 Mar;55(3):279-286. doi: 10.1080/00365521.2020.1731760. Epub 2020 Mar 2.
9
COVID-19 in IBD: The experience of a single tertiary IBD center.炎症性肠病合并 COVID-19：单中心经验。
Dig Liver Dis. 2021 Mar;53(3):271-276. doi: 10.1016/j.dld.2020.12.012. Epub 2020 Dec 26.
10
Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.接受免疫抑制药物治疗的炎症性肠病患者：大流行期间对 COVID-19 及医疗服务的看法。
Scand J Gastroenterol. 2021 May;56(5):545-551. doi: 10.1080/00365521.2021.1901308. Epub 2021 Mar 26.

引用本文的文献

1
COVID-19 and Inflammatory Bowel Disease.新型冠状病毒肺炎与炎症性肠病。
Gastroenterol Clin North Am. 2023 Mar;52(1):103-113. doi: 10.1016/j.gtc.2022.10.005. Epub 2022 Oct 31.
2
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case-Control Study (COVID-19-EII).炎症性肠病中新冠病毒病的危险因素：一项基于西班牙炎症性肠病注册数据库（ENEIDA）的全国性病例对照研究（COVID-19-EII）
J Clin Med. 2022 Dec 19;11(24):7540. doi: 10.3390/jcm11247540.
3
The Impact of Inflammatory Bowel Diseases and Related Medications on COVID-19 Severity and Outcome: A Tertiary Referral Center Experience from Turkey.
炎症性肠病及其相关药物对 COVID-19 严重程度和结局的影响：来自土耳其的一家三级转诊中心的经验。
Turk J Gastroenterol. 2022 Dec;33(12):1025-1032. doi: 10.5152/tjg.2022.22059.
4
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.COVID-19 对前瞻性欧洲队列研究中 IBD 患者的影响。
J Crohns Colitis. 2023 Jan 27;17(1):37-48. doi: 10.1093/ecco-jcc/jjac091.
5
Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment.跨膜丝氨酸蛋白酶 2 和血管紧张素转换酶 2 抗炎受体治疗 COVID-19/炎症性肠病。
World J Gastroenterol. 2021 Dec 14;27(46):7943-7955. doi: 10.3748/wjg.v27.i46.7943.
6
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study.韩国炎症性肠病患者 COVID-19 的临床病程：KASID 多中心研究。
J Korean Med Sci. 2021 Dec 13;36(48):e336. doi: 10.3346/jkms.2021.36.e336.
7
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.美沙拉嗪在炎症性肠病和 COVID-19 中的作用：基于全国范围数据的住院情况和不良院内结局。
Inflamm Bowel Dis. 2022 Oct 3;28(10):1513-1519. doi: 10.1093/ibd/izab299.
8
Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases - A Danish Prospective Population-Based Cohort Study with Individual-Level Data.炎症性肠病患者 COVID-19 的结局和长期影响 - 一项丹麦前瞻性基于人群的队列研究，具有个体水平数据。
J Crohns Colitis. 2022 Jun 24;16(5):757-767. doi: 10.1093/ecco-jcc/jjab192.
9
SARS-CoV-2 vaccination in patients with inflammatory bowel disease.炎症性肠病患者接种新型冠状病毒2型疫苗
GastroHep. 2021 Jul;3(4):212-228. doi: 10.1002/ygh2.473. Epub 2021 Jul 23.
10
Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives.肠病和 COVID-19 患者的管理：对当前证据和未来展望的综述。
Gastroenterol Hepatol. 2022 May;45(5):383-389. doi: 10.1016/j.gastrohep.2021.06.005. Epub 2021 Jun 23.